[Complete response in a case of anastomotic recurrence of rectal cancer treated with S-1 monotherapy].
A 63-year-old woman underwent a low anterior resection for rectal cancer in 2002.A n anastomotic recurrence was diagnosed in July 2011.S he rejected the possibility of colostomy as radical surgery.Chemotherapy consisting of capecitabine+ oxaliplatin (XELOX) or folinic acid, fluorouracil, and oxaliplatin (FOLFOX6) + bevacizumab were not possible because of high costs. In view of the lower costs and the potential for ambulation, S-1 monotherapy was started. After 3 months, a reduction in the recurrent lesion was observed.After 19 months, the recurrent lesion revealed a scar, which was judged by biopsy to be Group 1.We had achieved a pathological complete response (CR).The standard treatment for recurrent colon cancer is surgical resection or multidrug chemotherapy. However, in view of a patient's quality of life (QOL), S-1 monotherapy may be considered as a potential therapy.
Dept. of Surgery, Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers.
Akira
A
Kabashima
Dai
D
Kitagawa
Toshihiko
T
Nakamura
Naoko
N
Kondo
Seiichi
S
Teramoto
Genkichi
G
Saito
Tomoru
T
Funahashi
Eisuke
E
Adachi
Yoichi
Y
Ikeda
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010094:Oxonic Acid / Q000627:therapeutic use*; D011788:Quality of Life; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D012074:Remission Induction; D005641:Tegafur / Q000627:therapeutic use*
D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid